Novartis oncology news. 2 days ago · For investors watching large pharma, these two updates give a snapshot of how Novartis is positioning its portfolio across immunology and oncology. Oct 19, 2025 · Novartis, looking to expand its PSMA-targeting radiopharmaceutical Pluvicto into early prostate cancer, is heading to regulators, backed by a 28% reduction in the risk of disease progression or death in the PSMAddition trial in metastatic hormone-sensitive disease. Finovate conferences showcase cutting-edge banking and financial technology through a unique blend of short-form demos and key insights from thought-leaders. 5 billion people by the end of the decade. Dec 17, 2025 · In Brief This Week: Artios, Siren, Sarepta, Aktis Oncology, Nucleus Genomics, Novartis, LabCorp News items for the week of Feb. Uncover the latest research and company analysis to empower your investments. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Find the latest Novartis AG (NVS) stock quote, history, news and other vital information to help you with your stock trading and investing. Feb 28, 2026 · Headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a range of healthcare and pharmaceutical products, and is also involved in immuno-oncology research. .